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Abstract Historically, control brain tissue was classi-
fied as such mainly by clinical history, and underwent
limited neuropathological analysis. Significant progress
has been made in recent years with the collection of
more extensive clinical information and more specific
classifications of neurodegenerative disease, aided by
advances in histological processing and increasingly
sensitive detection methods. We hypothesised that this
may have resulted in certain pathologies previously go-
ing unidentified, due to insufficient block sampling and
an inadequate range of stains, resulting in the disease not
being recognised. We therefore investigated the sig-
nificance of changes to our own protocols for examining
control brain tissue before and after 2007. Control cases
that were originally assessed before 2007 were re-
assessed using our current staining protocol and anti-
bodies, and compared with age-matched cases post-2007.
We found that almost all cases that were originally de-
scribed as neuropathologically normal displayed some
level of pathology after re-analysis, with four cases
displaying what we have termed ‘major’ pathology that
previously went unidentified, emphasising on a small
scale the importance of accurate neuropathological ana-
lysis of control tissue, and highlighting the inherent
difficulty of traditionally classifying tissue simply as
‘disease’ or ‘control’. We hope our findings will stimu-
late debate within the brain banking community, with the
eventual aim being standardisation of protocols for
assessing controls across brain banks.
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Introduction
Cases of neurodegenerative diseases such as Alzheimer’s
disease are expected to double every 20 years globally
until 2040, consistent with an ageing population
(Mayeux and Stern 2012). Over the last 30 years, brain
banks have become an important resource in the study of
both neurodegenerative and neuropsychiatric illness,
providing researchers with well-defined collections of
both frozen and formalin-fixed tissue in conjunction with
accurate clinical information and neurological staging.
The use of control tissue for comparative studies is a
necessity. However, high-quality control tissue remains
relatively scarce, and researchers often cite the lack of
high-quality tissue as impeding research efforts (Sama-
rasekera et al. 2013). Factors contributing to the difficulty
in procuring such tissue include a general decline in au-
topsy rates (Burton and Underwood 2007) and recent organ
retention scandals in several countries, including the Alder
Hey scandal in the UK (Burton and Wells 2001; McGuone
and Kay 2004; Redfern et al. 2001; Sheach Leith 2007)
which have damaged the public’s perception of such ser-
vices. Additionally, awareness of brain donation amongst
potential donors is low (Eatough et al. 2012; Kuhta et al.
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2011) and recruitment of control donors is significantly
lower than disease patients (Bell et al. 2008). It is therefore
crucial that donated tissue described as clinically ‘normal’
is appropriately neuropathologically investigated to max-
imise its potential use.
Several neuropathological methods of staging exist for
various neurodegenerative diseases (Alafuzoff et al. 2006;
Braak and Braak 1991; Braak et al. 2003; Josephs et al.
2014) and detailed methods of processing FFPE and frozen
tissue for brain banking have been described (Vonsattel
et al. 1995; Vonsattel et al. 2008; Waldvogel et al. 2006).
However, there has so far been no attempt to standardise
staining protocols for control tissue. Deciding what is and
what is not suitable for designation as control tissue is often
inconsistent, compounding the difficulty in providing high-
quality, variable-matched tissue to researchers—who often
require different definitions of control tissue based on the
clinical/pathological nature of their study. Here, we de-
scribe and investigate our own protocols for handling
control tissue, with the aim of determining the correct
balance of thorough investigation with minimisation of
workload and cost.
Methods
We sought to identify differences in pathology revealed
using the neuropathological methods employed in the
MRC London Neurodegenerative Diseases Brain Bank
before and after 2007, when a new, more extensive in-
house protocol (Table 1) for assessing control tissue was
introduced, including the sampling of a wider range of
brain areas and the use of ‘new’ antibodies such as p62 and
TDP-43 which were not commercially available before
2007. This protocol is based upon the recommendations by
the BrainNet Europe consortium (Al-Sarraj 2008), to in-
clude amygdala, occipital lobe, middle frontal gyrus, su-
perior frontal gyrus, superior temporal gyrus,
hippocampus, midbrain and parietal lobe (see Table 1). In
both groups, only cases that were originally described as
clinically control (i.e. no history of neurological disease or
cognitive decline) and above 70 years of age were in-
cluded. Additionally, cases in the pre-2007 group were
recorded as having no significant pathology at the time of
the original investigation. All cases were originally donated
to the MRC London Neurodegenerative Disease Brain
Bank.
Histology
7-lm sections were cut from formalin-fixed paraffin-em-
bedded (FFPE) tissue. Haematoxylin and eosin staining
and modified Bielschowsky staining were performed on 7-
and 14-lm sections, respectively, according to standard
protocols.
Immunohistochemistry
The following antibodies were used for immunohisto-
chemistry: anti-tau (clone AT8, 1:500, Thermo Scientific,
Massachusetts, USA), anti-phosphorylated-TDP-43
(1:1500, Cosmo Bio, Tokyo, Japan), anti-b-amyloid (clone
A4, 1:6000, Covance, New Jersey, USA), anti-a-synuclein
(1:500, BD Transduction Laboratories, Kentucky, USA)
and anti-p62 (1:100, BD Transduction Laboratories, Ken-
tucky, USA). 7-lm paraffin sections were dewaxed, de-
hydrated and stained using the listed antibodies on an
automated immunohistochemistry platform (Leica
BONDMAX, Leica Biosystems). Antibody–antigen in-
teractions were located in the sections using a Polymer-
based detection kit (Novocastra Bond Polymer Refine
Detection, Leica Biosystems, Switzerland) and visualised
using 3,30-diaminobenzidine tetrahydrochloride as a chro-
mogen. Nuclei were counterstained using haematoxylin.
All cases were assessed by a Consultant Neuropathologist.
Post-2007
No additional sampling or staining was conducted for
cases that were processed after 2007 (n = 39). Each case
was retrospectively categorised according to the sig-
nificance of its previously identified pathology for
Table 1 Staining protocol for
control cases
The staining protocol (right)
was developed in house and
since 2007 is performed as
standard for all cases clinically
assessed as control
Fixed region taken Stains performed
Amygdala (including entorhinal cortex) H&E, a-synuclein, Tau, TDP-43
Occipital lobe at the level of the calcarine fissure H&E, b-amyloid, Tau
Middle frontal gyrus and white matter H&E, b-amyloid, Tau
Superior frontal gyrus including anterior cingulate gyrus H&E, a-synuclein
Hippocampus (including transentorhinal cortex) H&E, Bielschowsky, Tau, TDP-43
Midbrain H&E, a-synuclein, Tau
Parietal lobe and white matter H&E, Tau
Superior temporal gyrus H&E, b-amyloid, Tau, TDP-43
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Table 2 Post-2007 cases show differing levels of pathology despite clinical assessment as control
Year Sex Age Agonal state Neuropathological diagnosis
Minor pathology
2013 F 86 Coronary artery disease AD changes, BNE stage II, mild amyloid angiopathy
2013 F 81 Epilepsy AD changes, BNE stage I, hippocampal sclerosis
2013 M 90 Myocardial Infarction AD changes, BNE stage ?, mild focal amyloid angiopathy
2012 M 91 Stroke AD changes, BNE stage II
2012 F 85 Breast cancer AD changes, BNE stage II
2011 M 96 Not available AD changes, BNE stage II
2011 F 79 Not available AD changes, BNE stage II
2011 M 74 Respiration failure; cancer AD changes, BNE stage I
2011 M 97 Bronchopneumonia AD changes, BNE stage II
2011 F 93 Carcinomatosis AD changes, BNE stage I, mild amyloid angiopathy
2010 F 84 Metastatic breast cancer AD changes, BNE stage I, mild amyloid angiopathy
2009 F 84 Not available AD changes, BNE stage II
2011 F 84 Myocardial infarction AD changes, BNE stage II
Major pathology
2013 M 78 Pancreatic cancer Moderate to severe (diffuse) Cerebrovascular disease
2013 M 81 Prostate cancer Limbic stage of Alzheimer’s disease, consistent with BNE
stage III, mild amyloid angiopathy, hippocampal sclerosis
2013 M 80 Coronary stenosis AD changes, BNE stage III, mild to moderate small vessel
disease
2013a M 81 Pulmonary thromboembolism AD changes, BNE stage IV, brainstem predominant Lewy
body disease, mild amyloid angiopathy
2013a M 84 Colorectal cancer Occasional Lewy bodies and a-synuclein positive
inclusions in the substantia nigra and locus coeruleus.
TDP-43 inclusions in the amygdala, hippocampus and
parahippocampal gyrus
2013a F 78 NSTEMI AD changes, BNE stage II, small vessel cerebrovascular
disease; focal amyloid angiopathy, limbic TDP-43
pathology
2013 M 85 Heart failure AD changes, BNE stage III, very focal amyloid angiopathy
2012 M 87 Lung cancer AD changes, BNE stage III, widespread amyloid
angiopathy
2012 F 100 Cerebral ischaemia AGD, BNE stage III, mild amyloid angiopathy
2012 F 88 Not available AD changes, BNE stage III
2012 M 79 Pulmonary fibrosis AD changes, BNE stage III
2012 F 92 Skin cancer; diverticulitis AD changes, BNE stage III
2011 M 93 Perforated bowel AD changes, BNE stage IV, mild small vessel disease
2011 F 92 Peritonitis AD changes, BNE stage IV
2011 F 86 Aspiration pneumonia; stroke;
ischaemic heart disease
AD changes, BNE stage III
2011 F 86 Lung cancer AD changes, BNE stage III
2010 F 84 Lung cancer AD changes, BNE stage III
2011a M 74 Resp failure; exacerbation of COPD Mild neocortical Lewy body disease, intermediate
probability of AD changes, BNE stage III
2009 M 80 Cancer AD changes, BNE stage III, mild amyloid angiopathy
2009a F 99 Bronchopneumonia Posterior type Alzheimer’s disease intermediate stage
(NIA-Reagan); limbic TDP-43 positive structures
2012 M 78 Chest infection AD changes, BNE stage III
2011a M 88 Bronchopneumonia AD changes, BNE stage IV, amyloid angiopathy and limbic
TDP-43 pathology
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comparative purposes. Cases which showed no dis-
cernible pathology were designated ‘no pathology’. Cases
which showed one or more of the following pathologies
were designated ‘minor pathology’: mild amyloid an-
giopathy (i.e. only very occasional leptomeningeal vessels
staining for b-amyloid within their walls), mild cere-
brovascular disease and very localised tau deposition
consistent with modified Braak (BNE) stage I and II
(Braak et al. 2006). Cases which showed any of the fol-
lowing pathologies were designated ‘major pathology’:
any TDP-43 pathology, any a-synuclein positive Lewy
body pathology (including Lewy neurites), significant
amyloid angiopathy (at least moderate numbers of lep-
tomeningeal parenchymal vessels staining for b-amyloid
within their walls), significant cerebrovascular disease
(infarcts greater than 0.5 cm in diameter and/or at least
moderate white matter rarefaction with moderate
perivascular spacing and moderate thickening of vessel
walls) (Deramecourt et al. 2012), argyrophilic grain dis-
ease and widespread tau deposition consistent with at
least modified Braak (BNE) stage III–VI (Braak et al.
2006).
Pre-2007
7-lm FFPE sections were cut from the blocks used in
the original investigation and stained using automated
immunohistochemistry and the described protocol
(Table 1). Pre-2007 cases (n = 17) were at the time of
original investigation clinically and pathologically diag-
nosed as control tissue. Blocks from the original inves-
tigation were used wherever possible, however in all
cases it was necessary to use blocks processed from
recently archived wet tissue for some areas; for these an
additional p62 stain was performed on blocks requiring
a-synuclein to account for possible decreases in im-
munoreactivity resulting from prolonged formalin fixa-
tion (Pikkarainen et al. 2010). These cases were then
also categorised according to pathology severity detailed
above in the post-2007 group.
Results
Post-2007
Despite all cases being classified as control, no cases that
were described clinically as neurologically and cogni-
tively normal were completely devoid of pathology. In
35 % of cases this was minor, i.e. tau pathology in
keeping with BNE stage I–II, however 65 % displayed at
least one major pathology, such as tau pathology in
keeping with BNE stage III or TDP-43 pathology of
varying degrees. Several cases displayed limbic stage
Lewy body disease (see Table 2 for full diagnosis). One
interesting case in this group displayed pathology con-
sistent with basal ganglia predominant fronto-temporal
lobar degeneration and TDP-43 proteinopathy (FTLD-
TDP). However, when the patients’ medical history was
re-examined, a broad clinical diagnosis of neurodegen-
erative disease was discovered and the case was therefore
removed from the study.
Pre-2007
All re-analysed clinically control cases except one dis-
played some level of pathology (Table 3) with 24 %
showing pathology deemed major. Notably, one case (aged
Table 2 continued
Year Sex Age Agonal state Neuropathological diagnosis
2008a M 86 Not available AD changes, BNE stage III, AGD and limbic Lewy body
disease
2012a F 90 Transient ischaemic attack AD changes, BNE stage II, TDP-43 pathology in
hippocampus and amygdala, small blood vessel disease
AD Alzheimer’s disease, BNE BrainNet Europe, BDR brains for dementia research, COPD chronic obstructive pulmonary disease, NSTEMI non-
ST elevated myocardial infarction, AGD argyrophilic grain disease
a Several cases displayed TDP-43 pathology, as well as Lewy body disease. Interestingly, not a single case processed after 2007 displayed no
discernible pathology
Table 3 Pathology summary table
Post-2007 Pre-2007
No pathology
0 0 % 1 6 %
Minor pathology
13 35 % 12 70 %
Major pathology
24 65 % 4 24 %
Total
37 100 % 17 100 %
All cases before 2007, except one, displayed some form of pathology
after re-investigation using our current protocol
952 M. Nolan et al.
123
92 years) showed severe Alzheimer-type changes, includ-
ing plaques and tangles consistent with Alzheimer’s dis-
ease BNE stage V, limbic subtype of diffuse Lewy body
disease and significant amyloid angiopathy (see Table 4)
(Fig. 1). Additional a-synuclein staining of temporal, su-
perior and parietal cortices was carried out on this case to
confirm Lewy Body staging, after which the diagnosis was
altered to diffuse Lewy body disease of mild neocortical
subtype. When first investigated (albeit using limited
staining/sampling), this case was neuropathologically di-
agnosed as simply having ‘changes consistent with ageing’,
highlighting the increased range and depth of
neuropathology being performed now in comparison with
20 years ago.
Discussion
The pathological diagnosis of neurodegenerative diseases
now rests heavily on the use and interpretation of a range of
immunohistochemical stains. As the use of these sensitive
stains has developed, there has been a realisation that, to
make a sensible diagnosis in the background of clinical
information, there is a need to define a benchmark as to
Table 4 Pre-2007 cases that were re-analysed display previously unidentified pathologies





1990a M 70 Bronchopneumonia H&E, LFB, GFAP, Glees, A4,
Gallyas
Normal adult brain Normal brain
Minor pathology
1989 F 71 Bronchopneumonia None Normal adult brain AD changes, BNE stage ?
1991 F 80 Pulmonary
embolism
H&E, Bielschowsky Normal adult brain AD changes, BNE stage ?
1993 F 79 Ischaemic heart
disease
H&E, Bielschowsky Normal adult brain AD changes, BNE stage I
1993 M 78 Left ventricular
failure
H&E, Bielschowsky Normal adult brain AD changes, BNE stage I, mild
amyloid angiopathy
1993 M 74 Haemopericardium H&E, Bielschowsky Normal adult brain AD changes, BNE stage I
1998 F 71 Haemothorax H&E, LFB/N Normal adult brain AD changes, BNE stage I
2001 M 71 Colon cancer H&E, LFB/N, tau, ubiquitin,
a-synuclein, Gallyas, GFAP,
12F10
Normal adult brain AD changes, BNE stage I
2002 F 79 Carcinoma of lung H&E, tau, LFB Normal adult brain AD changes, BNE stage II
2002 M 78 GI haemorrhage H&E, Bielschowsky Normal adult brain AD changes, BNE stage II
2004 M 80 Cerebral amyloid
angiopathy
H&E, A4, Bielschowsky, tau Normal adult brain AD changes, BNE stage II
2004 F 89 Unknown H&E, LFB Normal adult brain AD changes, BNE stage II, mild
amyloid angiopathy
2006 F 82 Cancer Unknown Normal adult brain AD changes, BNE stage I
Major pathology
1990 F 80 Post-operative
haemorrhage
H&E, LFB, GFAP, Glees, A4,
Gallyas
Normal adult brain AD changes, BNE stage III, mild
small vessel disease
1992 M 70 Ischaemic heart
disease
H&E, Bielschowsky, Congo red,
GFAP
Normal adult brain AD changes, BNE stage III,
marked amyloid angiopathy
1993 F 89 Pulmonary emboli None Normal adult brain AD changes, BNE stage III,
amyloid angiopathy
1993b F 92 Myocardial
infarction
H&E, Bielschowsky Consistent with ageing AD changes: BNE stage V, mild
neocortical stage of diffuse Lewy
body disease, amyloid
angiopathy
AD Alzheimer’s disease, CAA cerebral amyloid angiopathy, DLBD diffuse Lewy body disease, SVD small vessel disease
a Only one case that was previously described as neuropathologically ‘normal’ was also found to be so after re-analysis
b Notably, one case from 1993 displays significant pathology which was largely unidentified when originally investigated
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what is an expected ‘‘normal range’’ of staining patterns for
these markers. In other words, there has become a greater
need as to how one defines ‘‘control brain tissue’’. It is well
recognised, for example, that during ageing the brain may
develop some tau pathology, without the patient being
cognitively impaired (Bennett et al. 2012; Crary et al.
2014; Mitchell et al. 2002; Price et al. 2009). The difficulty
comes therefore when one wants to compare some aspects
of a brain (with, for example, Alzheimer’s disease)
pathology with an age-matched ‘‘control’’ which also may
have some tau pathology albeit often mild. The purpose of
























Fig. 1 Demonstration of
different protein aggregates
across brain regions in a case
originally investigated in 1993.
These aggregates were only
identified after re-investigation
using our current control tissue
protocol. Re-investigation
revealed extensive tau
deposition consistent with BNE
stage V and the presence of
Lewy Bodies in the neocortex.
a Example of tau (AT8)
deposition in the hippocampus.
b Example of tau deposition in
the parietal cortex, arrow focal
tau staining. c Example of b-
amyloid (A4) deposition in the
hippocampus. d Example of b-
amyloid deposition in the
parietal cortex. e Example of
Lewy body formation
highlighted by a-synuclein
staining in the midbrain.
f Arrow example of Lewy body
formation highlighted by a-
synuclein staining in the frontal
cortex. g, h TDP43 reveals only




a 930, inset 9250, b 9100,
c 950, inset 9250, d 9100,
e 9400, f 9400, g 9200,
h 9400
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thorough blocking and staining protocol for ‘‘control’’
cases in our laboratory has made a difference in detecting
otherwise unexpected pathology, and if so the likely sig-
nificance of this.
After the more recent and comprehensive sampling and
staining protocols, we found that out of 17 ‘‘control’’ cases
originally assessed before 2007, all but one displayed some
level of pathology which were not reported originally; in-
cluding four cases which showed what we termed ‘‘major’’
pathology and 12 with ‘‘minor’’ pathology. These results
are in direct contrast to the original neuropathological de-
scriptions in which only limited sampling and stains were
conducted. The results therefore showed that a compre-
hensive blocking and staining protocol was required to
determine the extent of any pathological features in so-
called ‘‘control’’ cases. Since ‘‘control’’ brain tissue is the
most requested single condition from brain banks, it is
certainly important to know what pathological features (if
any) each such case shows.
The study of the alteration of the biochemical and
molecular components of proteins in specific neuro-ana-
tomical areas is becoming more important and therefore the
necessity of knowing the pathological features of corre-
sponding areas in ‘‘control’’ tissue has assumed greater
importance. For example, researchers interested in the
study of tau, a-synuclein or TDP-43 pathologies in the
hippocampus would require knowing to what extent such
pathology presents in this region in ‘‘control’’ cases. Our
study demonstrated that involvement of transrhinal and
entorhinal cortex and hippocampus with tau pathology is in
fact frequent in control brains from aged patients and a few
even have additional TDP-43 pathology. The importance of
this issue becomes more obvious when further sampling
and staining identified major pathological diagnosis such as
cases of Diffuse Lewy body dementia (DLBD) and amy-
loid angiopathy in our study.
Another point we found is that acquiring a more detailed
clinical history is as important as conducting extra staining
and sampling of the brain tissue. One of the cases referred
to our brain bank as ‘‘control’’ was found to have extensive
TDP43 pathology consistent with FTLD-TDP after more
sampling and staining was conducted which would not
have been detected without using the more comprehensive
recent protocol. However, after requesting further clinical
information, there was an indication of cognitive decline
and behavioural abnormalities, although these were not
clinically characterised before death and brain donation.
The importance of obtaining good clinical details and pa-
tient assessment before death becomes clearer in trying to
answer the question of what constitutes a ‘‘control’’ and
what we should consider ‘‘pathology within the normal
ageing process’’. While all the cases used above are age
matched over 70 years, it is widely acknowledged that a
certain level of tau pathology is often present with ageing,
such as in the case of Primary age-related tauopathy
(PART) (Crary et al. 2014). However, the precise corre-
lation between age, naturally accepted level of pathology
and suitability as control tissue is debatable. We suggest
that it may be better to view the pathology of ‘‘control’’
brains from aged donors as a spectrum of pathologies
rather than a discrete grouping and to be clearly matched
with clinical information before death—particularly
assessment of Mini mental state examination (MMSE),
especially given the debate surrounding whether patients
with mild pathology are essential in the early stage of
disease even without clinical symptoms. These issues raise
the question of the actual usefulness of accepting ‘‘ad-hoc’’
brain donation without prior clinical assessment as has
been our practice for some time.
Lastly, our approach has obvious limitations. For ex-
ample, the neuropathological diagnosis of Alzheimer’s
Disease is based around tau pathology and BNE staging.
We only considered to a lesser degree the compounding
effect of co-existing pathologies such as vascular pathol-
ogy which would require further consideration. Our
sampling protocol is based on broad sampling of brain
tissue and a number of immunohistochemical stains;
however, it may not be applicable in all instances and all
brain banks. The issue of how many regions to sample
and how many immunohistochemical tests to request on
clinically defined control tissue is to a certain degree a
matter of pathologist preference and often a matter of cost
for individual brain banks. Our diagnostic protocol did not
until recently provide for the investigation of the earliest
pathological manifestation of possible Lewy body disease
in the medulla and pons, but adding further stains to an
ever-increasing list does present potential economic
problems.
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